NCT04105270 2025-09-11
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
Masonic Cancer Center, University of Minnesota
GlaxoSmithKline
GlaxoSmithKline